Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 54,244 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 54,244 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the sale, the chief accounting officer now owns 54,410 shares of the company’s stock, valued at $1,360,250. This represents a 49.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Monday, February 3rd, Sandra Calvin sold 3,348 shares of Travere Therapeutics stock. The stock was sold at an average price of $20.12, for a total value of $67,361.76.
• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.94, for a total transaction of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total transaction of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $23.72 on Friday. The firm has a market cap of $1.85 billion, a PE ratio of -5.21 and a beta of 0.72. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $25.29. The company’s fifty day simple moving average is $19.14 and its 200-day simple moving average is $16.01. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jennison Associates LLC acquired a new stake in shares of Travere Therapeutics in the fourth quarter valued at about $14,222,000. Renaissance Technologies LLC grew its stake in Travere Therapeutics by 28.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company’s stock valued at $41,974,000 after purchasing an additional 534,500 shares in the last quarter. Invesco Ltd. increased its position in shares of Travere Therapeutics by 135.2% during the 4th quarter. Invesco Ltd. now owns 858,942 shares of the company’s stock worth $14,963,000 after purchasing an additional 493,736 shares during the last quarter. abrdn plc bought a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $6,829,000. Finally, Prudential Financial Inc. boosted its holdings in shares of Travere Therapeutics by 60.5% in the 4th quarter. Prudential Financial Inc. now owns 969,141 shares of the company’s stock valued at $16,882,000 after buying an additional 365,200 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TVTX. Evercore ISI boosted their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday. Barclays boosted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Scotiabank increased their target price on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $27.77.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.